Home Cart Sign in  
Chemical Structure| 62284-79-1 Chemical Structure| 62284-79-1

Structure of (-)-p-Bromotetramisole oxalate
CAS No.: 62284-79-1

Chemical Structure| 62284-79-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

(-)-p-Bromotetramisole Oxalate is a potent and non-specific alkaline phosphatase inhibitor.

Synonyms: 6-Bromolevamisole oxalate; L-p-Bromotetramisole oxalate; L-para-Bromotetramisole

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (-)-p-Bromotetramisole oxalate

CAS No. :62284-79-1
Formula : C13H13BrN2O4S
M.W : 373.22
SMILES Code : BrC1=CC=C([C@@H]2N=C3SCCN3C2)C=C1.O=C(O)C(O)=O
Synonyms :
6-Bromolevamisole oxalate; L-p-Bromotetramisole oxalate; L-para-Bromotetramisole
MDL No. :MFCD00070406
InChI Key :ZULBIBHDIQCNIS-HNCPQSOCSA-N
Pubchem ID :2724023

Safety of (-)-p-Bromotetramisole oxalate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312
Precautionary Statements:P280

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
rat kidney cells 0.1 mM 15 min L-p-bromotetramisole significantly reduced adenosine levels in renal venous perfusate. Hypertension. 2017 Mar;69(3):484-493
rat kidney cells 0.1 mM 1 hour L-p-bromotetramisole significantly decreased renal venous levels of 5'-AMP and adenosine by 61% and 62%, respectively. Hypertension. 2017 Mar;69(3):484-493
rat mesenteric vasculature 200 μM had no further effect on either mesenteric TNAP activity or norepinephrine-induced vasoconstriction Hypertension. 2020 Oct;76(4):1308-1318
rat mesenteric vasculature 100 μM further reduced mesenteric TNAP activity and caused an additional significant right-shift of the norepinephrine concentration versus vasoconstriction relationship Hypertension. 2020 Oct;76(4):1308-1318
rat mesenteric vasculature 50 μM significantly reduced TNAP activity and caused a significant 9.0-fold rightward-shift in the norepinephrine concentration versus vasoconstriction relationship Hypertension. 2020 Oct;76(4):1308-1318

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Anesthetized rat model Intravenous 30 mg/kg Two slow bolus injections, 15 minutes apart L-p-bromotetramisole significantly attenuated the norepinephrine-induced increases in blood pressure and renal vascular resistance. Hypertension. 2017 Mar;69(3):484-493
Sprague-Dawley rats Anesthetized rats Intravenous injection 30 mg/kg IV bolus Blood samples were taken at 0.25, 0.5, 1, 2, 4, 8 and 10 hr after single injection Determined the pharmacokinetic parameters of L-p-bromotetramisole in plasma, achieving plasma levels of approximately 60 μmol/L and inhibited mesenteric vascular responses to exogenous norepinephrine and sympathetic nerve stimulation Hypertension. 2020 Oct;76(4):1308-1318

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.68mL

0.54mL

0.27mL

13.40mL

2.68mL

1.34mL

26.79mL

5.36mL

2.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories